CTRI/2018/11/016349
Recruiting
Phase 3
Biomarker-based optimization of adjuvant therapy in glioblastoma - BOAT
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: C719- Malignant neoplasm of brain, unspecified
- Sponsor
- Tata Memorial Hospital
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Newly\-diagnosed GBM or variants (WHO grade IV) proven on histopathology of tumor tissues
- •resected at decompressive surgery/biopsy 2\. Adults \>\=18 years of age at time of enrolment 3\. Availability of
- •tumor tissues for assessing MGMT methylation status 4\. KarnofskyPerformance Status (KPS) \>\=70 and
- •Neurologic Performance Status (NPS) 0\-1 5\. Adequate bone marrow reserve (absolute neutrophil count \>1500
- •and platelet count \>1,00,000\) 6\. Normal liver and renal function tests 7\. Written informed consent
Exclusion Criteria
- •1\. Recurrent/progressive GBM 2\. Transformed secondary GBM from a previous lowergrade
- •glioma 3\. Diffuse gliomatosis necessitating whole brain irradiation 4\. Prior history of any other
- •malignancy 5\. Concurrent treatment with any other investigational agent 6\. Any inter\-current illness that
- •precludes safe administration of TMZ 7\. Unwillingness to comply with proposed therapy and/or follow\-up
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Identification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by analyses of individual patients' data from large randomized controlled trialsgastric cancerJPRN-UMIN000028411Tsuboi Cancer Center Hospital3
Recruiting
Phase 2
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCEsophageal Squamous Cell CarcinomaNCT06601309Fujian Medical University Union Hospital90
Completed
Phase 2
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerBreast CancerNCT01779206West German Study Group4,936
Completed
Phase 2
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerBreast CancerNCT01781338West German Study Group4,936
Recruiting
Phase 2
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast CancerBreast CancerBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIINCT05288777University of Virginia45